Antitumor necrotic factor agent promotes BMP-2-induced ectopic bone formation

Journal of Bone and Mineral Metabolism

Volumn 28, Issue 2, 2010, Pages 157-164

  Eguchi, Yoshitaka ^a   Wakitani, Shigeyuki ^a   Imai, Yuuki ^a   Naka, Yoshifumi ^a   Hashimoto, Yuusuke ^a   Nakamura, Hiroaki ^a   Takaoka, Kunio ^a  

^a OSAKA UNIVERSITY   (Japan)

Author keywords

Etanercept; Osteoblast; Osteoclast; Tumor necrosis factor bone morphogenetic protein 2

Indexed keywords

ALKALINE PHOSPHATASE; CALCIUM; EMBREL; ETANERCEPT; MACROGOL; PHOSPHATE; PLACEBO; POLYDIOXANONE; POLYLACTIC ACID; RECOMBINANT BONE MORPHOGENETIC PROTEIN 2; UNCLASSIFIED DRUG; BONE DENSITY CONSERVATION AGENT; BONE MORPHOGENETIC PROTEIN; HYBRID PROTEIN; IMMUNOGLOBULIN G; RECOMBINANT HUMAN BONE MORPHOGENETIC PROTEIN 2; RECOMBINANT HUMAN BONE MORPHOGENETIC PROTEIN-2; RECOMBINANT PROTEIN; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; BONE DEVELOPMENT; BONE METABOLISM; BONE MINERAL; BONE REGENERATION; CELL COUNT; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DOSE COMPARISON; DRUG POTENTIATION; EMBEDDING; IN VIVO STUDY; MALE; MORPHOMETRICS; MOUSE; NONHUMAN; OSSIFICATION; OSTEOBLAST; PRIORITY JOURNAL; SINGLE DRUG DOSE; ANIMAL; BONE DENSITY; CHEMISTRY; COMPARATIVE STUDY; CYTOLOGY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; DRUG IMPLANT; HISTOLOGY; INSTITUTE FOR CANCER RESEARCH MOUSE; OSTEOCLAST; SUBCUTANEOUS DRUG ADMINISTRATION; TIBIA;

ANIMALS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE MORPHOGENETIC PROTEINS; BONE REGENERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG IMPLANTS; DRUG SYNERGISM; IMMUNOGLOBULIN G; INJECTIONS, SUBCUTANEOUS; MALE; MICE; MICE, INBRED ICR; OSTEOBLASTS; OSTEOCLASTS; OSTEOGENESIS; RECEPTORS, TUMOR NECROSIS FACTOR; RECOMBINANT FUSION PROTEINS; RECOMBINANT PROTEINS; TIBIA; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77952529848     PISSN: 09148779     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00774-009-0127-x     Document Type: Article

References (36)

1. Li P, Schwarz EM, O'Keefe RJ, Ma L, Boyce BF, Xing L (2004) RANK signaling is not required for TNF-alpha-mediated increase in CD11(hi) osteoclast precursors but is essential for mature osteoclast formation in TNFalpha-mediated inflammatory arthritis. J Bone Miner Res 19:207-213
2. Takayanagi H, Ogasawara K, Hida S, Chiba T, Murata S, Sato K, Takaoka A, Yokochi T, Oda H, Tanaka K, Nakamura K, Taniguchi T (2000) T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. Nature (Lond) 408:600-605
3. Theill LE, Boyle WJ, Penninger JM (2002) RANK-L and RANK: T cells, bone loss, and mammalian evolution. Annu Rev Immunol 20:795-823
4. Chopin F, Garnero P, le Henanff A, Debiais F, Daragon A, Roux C, Sany J, Wendling D, Zarnitsky C, Ravaud P, Thomas T (2008) Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis. Ann Rheum Dis 67:353-357
5. Kageyama Y, Takahashi M, Nagafusa T, Torikai E, Nagano A (2008) Etanercept reduces the oxidative stress marker levels in patients with rheumatoid arthritis. Rheumatol Int 28:245-251
6. Nakase T, Takaoka K, Masuhara K, Shimizu K, Yoshikawa H, Ochi T (1997) Interleukin-1 beta enhances and tumor necrosis factor-alpha inhibits bone morphogenetic protein-2-induced alkaline phosphatase activity in MC3T3-E1 osteoblastic cells. Bone (NY) 21:17-21
7. Yamashita M, Otsuka F, Mukai T, Otani H, Inagaki K, Miyoshi T, Goto J, Yamamura M, Makino H (2008) Simvastatin antagonizes tumor necrosis factor-alpha inhibition of bone morphogenetic proteins-2-induced osteoblast differentiation by regulating Smad signaling and Ras/Rho-mitogen-activated protein kinase pathway. J Endocrinol 196:601-613
8. Kaneki H, Guo R, Chen D, Yao Z, Schwarz EM, Zhang YE, Boyce BF, Xing L (2006) Tumor necrosis factor promotes Runx2 degradation through up-regulation of Smurf1 and Smurf2 in osteoblasts. J Biol Chem 281:4326-4333
9. Kaymakcalan Z, Sakorafas P, Bose S, Scesney S, Xiong L, Hanzatian DK, Salfeld J, Sasso EH (2009) Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor. Clin Immunol 131:308-316
10. Scallon B, Cai A, Solowski N, Rosenberg A, Song XY, Shealy D, Wagner C (2002) Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 301:418-426
11. Saito N, Okada T, Horiuchi H, Murakami N, Takahashi J, Nawata M, Ota H, Nozaki K, Takaoka K (2001) A biodegradable polymer as a cytokine delivery system for inducing bone formation. Nat Biotechnol 19:332-335
12. Kato M, Toyoda H, Namikawa T, Hoshino M, Terai H, Miyamoto S, Takaoka K (2006) Optimized use of a biodegradable polymer as a carrier material for the local delivery of recombinant human bone morphogenetic protein-2 (rhBMP-2). Biomaterials 27:2035-2041
13. Suzuki A, Terai H, Toyoda H, Namikawa T, Yokota Y, Tsunoda T, Takaoka K (2006) A biodegradable delivery system for antibiotics and recombinant human bone morphogenetic protein-2: a potential treatment for infected bone defects. J Orthop Res 24:327-332 (Pubitemid 43772992)
14. Toyoda H, Terai H, Sasaoka R, Oda K, Takaoka K (2005) Augmentation of bone morphogenetic protein-induced bone mass by local delivery of a prostaglandin E EP4 receptor agonist. Bone (NY) 37:555-562
15. Yano K, Hoshino M, Ohta Y, Manaka T, Naka Y, Imai Y, Sebald W, Takaoka K (2009) Osteoinductive capacity and heat stability of recombinant human bone morphogenetic protein-2 produced by Escherichia coli and dimerized by biochemical processing. J Bone Miner Metab 27:355-363
16. Zhao B, Katagiri T, Toyoda H, Takada T, Yanai T, Fukuda T, Chung UI, Koike T, Takaoka K, Kamijo R (2006) Heparin potentiates the in vivo ectopic bone formation induced by bone morphogenetic protein-2. J Biol Chem 281:23246-23253
17. Nakamura T, Imai Y, Matsumoto T, Sato S, Takeuchi K, Igarashi K, Harada Y, Azuma Y, Krust A, Yamamoto Y, Nishina H, Takeda S, Takayanagi H, Metzger D, Kanno J, Takaoka K, Martin TJ, Chambon P, Kato S (2007) Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts. Cell 130:811-823
18. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR (1987) Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2:595-610
19. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS et al (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89:309-319
20. Kawaguchi A, Nakaya H, Okabe T, Tensho K, Nawata M, Eguchi Y, Imai Y, Takaoka K, Wakitani S (2009) Blocking of tumor necrosis factor activity promotes natural repair of osteochondral defect in rabbit knee. Acta Orthopaedica (in press)
21. van der Heijde DM (1995) Joint erosions and patients with early rheumatoid arthritis. Br J Rheumatol 34(suppl 2):74-78
22. Quinn MA, Conaghan PG, Emery P (2001) The therapeutic approach of early intervention for rheumatoid arthritis: what is the evidence? Rheumatology (Oxf) 40:1211-1220
23. Mohler KM, Torrance DS, Smith CA, Goodwin RG, Stremler KE, Fung VP, Madani H, Widmer MB (1993) Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 151:1548-1561
24. Scott DL, Kingsley GH (2006) Tumor necrosis factor inhibitors for rheumatoid arthritis. N Engl J Med 355:704-712
25. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, Genovese MC, Wasko MC, Moreland LW, Weaver AL, Markenson J, Finck BK (2000) A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 343:1586-1593
26. Gerstenfeld LC, Cho TJ, Kon T, Aizawa T, Tsay A, Fitch J, Barnes GL, Graves DT, Einhorn TA (2003) Impaired fracture healing in the absence of TNF-alpha signaling: the role of TNF-alpha in endochondral cartilage resorption. J Bone Miner Res 18:1584-1592
27. Hashimoto J, Yoshikawa H, Takaoka K, Shimizu N, Masuhara K, Tsuda T, Miyamoto S, Ono K (1989) Inhibitory effects of tumor necrosis factor alpha on fracture healing in rats. Bone (NY) 10:453-457
28. Hong JH, Lee GT, Lee JH, Kwon SJ, Park SH, Kim SJ, Kim IY (2009) Effect of bone morphogenetic protein-6 on macrophages. Immunology 128:442-450
29. Urist MR (1965) Bone: formation by autoinduction. Science 150:893-899
30. Wozney JM, Rosen V, Celeste AJ, Mitsock LM, Whitters MJ, Kriz RW, Hewick RM, Wang EA (1988) Novel regulators of bone formation: molecular clones and activities. Science 242:1528-1534
31. Hirata K, Mizuno A, Yamaguchi A (2007) Transplantation of skin fibroblasts expressing BMP-2 contributes to the healing of critical-sized bone defects. J Bone Miner Metab 25:6-11
32. Nakase T, Yoshikawa H (2006) Potential roles of bone morphogenetic proteins (BMPs) in skeletal repair and regeneration. J Bone Miner Metab 24:425-433
33. Bhandari M, Guyatt GH, Swiontkowski MF, Schemitsch EH (2001) Treatment of open fractures of the shaft of the tibia. J Bone Joint Surg [Br] 83:62-68
34. Valentin-Opran A, Wozney J, Csimma C, Lilly L, Riedel GE (2002) Clinical evaluation of recombinant human bone morphogenetic protein-2. Clin Orthop Relat Res 395:110-120
35. Yoneda M, Terai H, Imai Y, Okada T, Nozaki K, Inoue H, Miyamoto S, Takaoka K (2005) Repair of an intercalated long bone defect with a synthetic biodegradable bone-inducing implant. Biomaterials 26:5145-5152
36. Namikawa T, Terai H, Hoshino M, Kato M, Toyoda H, Yano K, Nakamura H, Takaoka K (2007) Enhancing effects of a prostaglandin EP4 receptor agonist on recombinant human bone morphogenetic protein-2 mediated spine fusion in a rabbit model. Spine 32:2294-2299